COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,731 Articles (22,502 medRxiv, 8,229 bioRxiv)

Most recent first Previous |  Page 879: Articles 8781-8790  | Next

Neonatal and Maternal Outcome of COVID-19 positive women in Sri Lanka: Secondary Analysis using National COVID-19 Positive Pregnant Women Surveillance
Kumarasinghe, M., Kasturiaratchi, K., Jayakody, H., Irfaan, S., Samarasinghe, W., Dassanayake, H., Godakandage, S., de Silva, C.
10.1101/2022.02.10.22270732 — Posted: 2022-02-13
Food intake patterns, social determinants and emotions during COVID-19 confinement: an online survey among adults in Panama.
Rios, M., Subinas, J., Delgado, C., Torres, E., Goodridge, A., Cubilla-Alfaro, I.
10.1101/2022.02.11.22270876 — Posted: 2022-02-13 Discussion: Onsite
Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK)
Vivaldi, G., Jolliffe, D. A., Faustini, S., Holt, H., Perdek, N., Talaei, M., Tydeman, F., Chambers, E. S., Cai, W., Li, W., Gibbons, J. M., Pade, C., McKnight, A., Shaheen, S. O., Richter, A. G., Martineau, A. R.
10.1101/2022.02.11.22270667 — Posted: 2022-02-13
Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already Protected by Natural or Vaccine-Induced Immunity
Shrestha, N. K., Shrestha, P., Burke, P. C., Nowacki, A. S., Terpeluk, P., Gordon, S. M.
10.1101/2022.02.10.22270744 — Posted: 2022-02-13 Discussion: Onsite
In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
Checkmahomed, L., Du Pont, V., Riola, N. C., Perry, J., Li, J., Porter, D. P., Boivin, G.
10.1101/2022.02.07.479493 — Posted: 2022-02-12
Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan
Ayubov, M. S., Buriev, Z. T., Mirzakhmedov, M. K., Yusupov, A. N., Usmanov, D. E., Shermatov, S. E., Ubaydullaeva, K. A., Abdurakhmonov, I.
10.1101/2022.02.10.479714 — Posted: 2022-02-11
An efficient and cost-effective method for directed mutagenesis at multiple dispersed sites - a case study with Omicron Spike DNA
Rani, R., Parsa, K. V. L., Chatti, K. R., Sevilimedu, A.
10.1101/2022.02.10.480017 — Posted: 2022-02-11
Impact of COVID-19 pandemic and anti-pandemic measures on tuberculosis, viral hepatitis, HIV/AIDS and malaria - a systematic review
Kessel, B., Heinsohn, T., Ott, J. J., Wolff, J., Hassenstein, M. J., Lange, B.
10.1101/2022.02.10.22270782 — Posted: 2022-02-11
Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment
Kumar, S., Karuppanan, K., Subramaniam, G.
10.1101/2022.02.11.480029 — Posted: 2022-02-11
Molecular Dynamics Simulations Studies On The Effects Of Mutations On The Binding Affinities Between SARS-CoV-2 Spike RBD And Human ACE2
Arora, S., Patra, J.
10.1101/2022.02.11.480063 — Posted: 2022-02-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).